Citadel Advisors
PTHS

Citadel Advisors’s Pelthos Therapeutics PTHS Stock Holding History

Citadel Advisors’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$425K Buy
+15,046
New +$386K ﹤0.01% 10278
2024
Q3 		– Sell
-1,871
Closed -$24.7K – 15408
2024
Q2 		$24.7K Buy
+1,871
New +$31.5K ﹤0.01% 12452

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Citadel Advisors's PTHS Position: Q2 2026 in Review

Citadel Advisors opened a new position in Pelthos Therapeutics (PTHS) in Q2 2026: 15,046 shares worth $425K. The stake represents ﹤0.01% of the portfolio and ranks #10278 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in PTHS as recently as Q2 2024.

Citadel Advisors first reported a position in PTHS in Q2 2024 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • Citadel Advisors held 15,046 shares of Pelthos Therapeutics worth $425K as of Q2 2026.
  • Pelthos Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Pelthos Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #10278 holding.
  • Citadel Advisors first reported a position in Pelthos Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.